Previous terms
continue: This approval only covers the baseline wave of data
collection. A full revision is necessary for the second wave.
Before submitting the second wave of data collection to OMB for
approval under the PRA, NIDA/FDA should report to OMB regarding the
response rates associated with the baseline (screening, interview
completion, and bio-specimen response, the results of their
nonresponse analysis and statistical approach for addressing
non-response, as well as implications for the study going forward.
NIDA and FDA will create a public use dataset from each wave’s
data, making it available to the public on-line within 18 months of
completion of each wave. Data underlying government-funded
scientific publications will be made available to the public,
consistent with NIH guidelines for implementing OSTP’s Public
Access to the Results of Federally Funded Research. This study is
not specifically designed to provide nationally representative
estimates of prevalence. As such, FDA and NIDA will always present
such cross-sectional prevalence estimates in conjunction with
estimates from HHS’ signature nationally representative studies
such as CPS-TUPS, NHIS, NATS, and NSDUH . Results based on the
bio-specimen data cannot publicly disseminated until OMB approves a
change request under the PRA that explains the statistical approach
to be applied to the bio-specimen data to address potential
non-response bias from lower consent and cooperation rates with
this aspect of the study.
Inventory as of this Action
Requested
Previously Approved
11/30/2015
11/30/2015
11/30/2015
560,451
0
560,451
136,889
0
136,889
0
0
0
Enactment of the FSPTCA granted FDA
regulatory authority over tobacco products to protect public health
and reduce tobacco use among Americans, particularly young people.
The NIH, through NIDA, is partnering with FDA's newly established
Center for Tobacco Products (CTP) in a large-scale collaboration to
conduct the PATH study. This national longitudinal study of tobacco
use and health will provide epidemiological, population-based data
about attitudes and perceptions related to the use of different
existing and emerging tobacco products; patterns and trends in use
of existing and emerging tobacco products; knowledge of the
contents of tobacco products and of the consequences of their use;
and on near- and longer-term health outcomes associated with
tobacco product use. These data will advance the scientific
knowledge base on tobacco use behaviors and health; and serve to
establish a regulatory science framework for FDA's development,
implementation, and evaluation of effective product regulations to
reduce tobacco-related diseases, disabilities, and deaths in the
U.S. population. The PATH study also fills a data gap with its
longitudinal cohort design. It is the only national longitudinal
study of tobacco use. As such, this study provides a unique
opportunity to monitor and assess changes over time in patterns of
use of tobacco products among study respondents. The study will
collect national longitudinal survey data from a cohort of
approximately 59,587 current, former, and never tobacco product
users ages 12 years and older in the U.S. Biospecimens will also be
collected from adult respondents to assess objective measures of
exposure and prospectively monitor indicators of tobacco
use-related harm.
US Code:
42
USC 285o Name of Law: Title 42 USC 285o
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.